BenevolentAI’s CEO Joerg Moeller is stepping down effective immediately, the London biotech said Thursday, in the latest leadership shakeup atop the company.
Since going public in early 2022 via a SPAC, BenevolentAI’s stock price has fallen over 90%. Its lead drug candidate fell short in a mid-stage…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
Recognitions underscore breakthrough innovations, meaningful client outcomes at scale, and leadership driving healthcare’s AI transformation LEHI, Utah and LOUISVILLE, Ky., Aug. 25, 2025 /PRNewswire/ — Waystar (Nasdaq: WAY), a provider of leading healthcare payment software, […]
SALT LAKE CITY–(BUSINESS WIRE)–The Ryan and Ashley Smith Foundation today announced a $20 million donation to Utah’s Intermountain Primary Children’s Hospital, a 100-year-old, top-ranked pediatric hospital. The money will help power groundbreaking pediatric cancer research […]
SAN FRANCISCO, June 4, 2023 /PRNewswire/ — Vial, a global tech-first CRO providing next-generation clinical trial management services, announced it will be sponsoring and presenting at the 2023 Clinical Trials at the Summit (CTS) in […]
Copyright © 2026 Biotech Networks
